Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
RECRUITING
Trial end date:
2028-04-30
Target enrollment:
Participant gender:
Summary
This is the first in human study of KK2845. This trial consists of Part 1 (Dose escalation) and Part 2 (Backfill). In Part 1, the maximum tolerated dose (MTD) will be determined while evaluating the safety and tolerability of KK2845 in patients with relapsed or refractory acute myeloid leukemia. Part 2 will collect additional data at tolerated doses of KK2845.